Skip to main content

Advertisement

Table 2 Transition probabilities applied in the model

From: Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

Parameter Probability Reference
Discontinuation SLIT (5-grass tablet) Year 1 0.29 [27]
Year 2 0.28 [27]
Discontinuation SCIT (allergoid mix) Year 1 0.41 [27]
Year 2 0.34 [27]
Developing asthma with symptomatic treatment 0.0046 [28]
Relative risk developing asthma (AIT vs. symptomatic treatment) 0.505 [29,30]
All population mortality* 0.00046 [31]
Asthma mortality* 0.00069 [32]
  1. *Probabilities represent mortality at start of the analysis (29 years).